Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management

被引：43
|
作者：
Savoia, Paola [1 ,2 ]
Astrua, Chiara [1 ]
Fava, Paolo [1 ]
机构：
[1] Univ Turin, Dept Med Sci, Turin, Italy
[2] A Avogadro Univ Eastern Piedmont, Dept Hlth Sci, Novara, Italy
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期
关键词：
anti-CTL-A4; ipilimumab; immunotherapy; melanoma treatment; toxicity; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; T-CELL RESPONSES; RECOMBINANT INTERLEUKIN-2 THERAPY; PRETREATED ADVANCED MELANOMA; EXPANDED ACCESS PROGRAM; CTLA-4; BLOCKADE; BRAIN METASTASES; PHASE-2; TRIAL; ADVERSE EVENTS; DOUBLE-BLIND;
D O I：
10.1080/21645515.2015.1129478
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.
引用
收藏
页码：1092 / 1101
页数：10
相关论文
共 50 条
  • [1] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [2] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [3] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [4] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
    Imafuku, Keisuke
    Yoshino, Koji
    Yamaguchi, Kei
    Tsuboi, Satoshi
    Ohara, Kuniaki
    Hata, Hiroo
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
  • [5] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
    Keisuke Imafuku
    Koji Yoshino
    Kei Yamaguchi
    Satoshi Tsuboi
    Kuniaki Ohara
    Hiroo Hata
    British Journal of Cancer, 2017, 116 : e14 - e14
  • [6] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
    Prithviraj, Prashanth
    McArthur, Grant A.
    Atkinson, Victoria
    Parente, Phillip
    Andrews, Miles Cameron
    Parakh, Sagun
    Cebon, Jonathan S.
    Klein, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Ipilimumab.: Cancer immunotherapy, human anti-CTLA-4 MAb.
    Sobera, LA
    Bayés, M
    DRUGS OF THE FUTURE, 2006, 31 (03) : 196 - 202
  • [8] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [9] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
    Samantha Bowyer
    Prashanth Prithviraj
    Paul Lorigan
    James Larkin
    Grant McArthur
    Victoria Atkinson
    Michael Millward
    Muoi Khou
    Stefan Diem
    Sangeetha Ramanujam
    Ben Kong
    Elizabeth Liniker
    Alexander Guminski
    Phillip Parente
    Miles C Andrews
    Sagun Parakh
    Jonathan Cebon
    Georgina V Long
    Matteo S Carlino
    Oliver Klein
    British Journal of Cancer, 2017, 116 : e15 - e15
  • [10] Anti-CTLA-4 antibodies A major therapeutic advance in metastatic melanoma treatment
    Robert, Caroline
    Mateus, Christine
    M S-MEDECINE SCIENCES, 2011, 27 (10): : 850 - 858
12345